#BEGIN_DRUGCARD DB01390

# AHFS_Codes:
Not Available

# ATC_Codes:
B05CB04
B05XA02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Alka-Seltzer Flavoured (Acetylsalicylic Acid + Citric Acid + Sodium Bicarbonate)
Amo Endosol Extra (alcium Chloride + Dextrose + Glutathione Disulfide + Magnesium Chloride + Potassium Chloride + Sodium Bicarbonate + Sodium Chloride + Sodium Phosphate Dibasic)
Artrol (Antipyrine + Cimicifuga Racemosa + Methyl Salicylate + Sodium Bicarbonate + Sodium Salicylate + Taraxacum Officinale Weber)
Baros Effervescent Granules (Sodium Bicarbonate + Tartaric Acid)
Bicarbonate Concentrate D16000 (Sodium Bicarbonate + Sodium Chloride)
Bicarbonate Concentrate D16001 (Sodium Bicarbonate + Sodium Chloride)
E-Z-Gas 2 (Citric Acid + Sodium Bicarbonate)
Woodward's Gripe Water (Oil of Dill + Sodium Bicarbonate)

# Brand_Names:
Not Available

# CAS_Registry_Number:
144-55-8

# ChEBI_ID:
32139

# Chemical_Formula:
CHNaO3

# Chemical_IUPAC_Name:
sodium hydrogen carbonate

# Chemical_Structure:
Not Available

# Creation_Date:
2007-07-08 10:59:29 -0600

# DPD_Drug_ID_Number:
2280884

# Description:
Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

# Dosage_Forms:
Liquid	Oral
Powder	Oral
Solution	Intravenous
Solution / drops	Oral
Tablet	Oral

# Drug_Category:
Antidiarrheals

# Drug_Interactions:
Atazanavir	This gastric pH modifier decreases the levels/effect of atazanavir
Benzphetamine	Alkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered.
Deferiprone	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
Eltrombopag	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
Lithium	The urine alkalizer decreases the effect of lithium
Memantine	Possible increased levels of memantine
Methenamine mandelate	Urine alkalizer decreases the effect of methenamine
Quinidine	The antacid increases the effect of quinidine
Ticlopidine	Sodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart.
Tipranavir	Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir.
Trandolapril	Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+005 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sodium bicarbonate

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1

# InChI_Key:
InChIKey=UIIMBOGNXHQVGW-UHFFFAOYSA-M

# Indication:
Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.

# KEGG_Compound_ID:
C12603

# KEGG_Drug_ID:
D01203

# LIMS_Drug_ID:
1390

# Mechanism_Of_Action:
Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]

# Melting_Point:
Decomposes around 50 °C

# Molecular_Weight_Avg:
84.0066

# Molecular_Weight_Mono:
83.982338573

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451375

# Pharmacology:
Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.

# Predicted_LogP_Hydrophobicity:
-0.06

# Predicted_LogS:
0.96

# Predicted_Water_Solubility:
7.64e+02 g/l

# Primary_Accession_No:
DB01390

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
516892

# PubChem_Substance_ID:
46507049

# RxList_Link:
http://www.rxlist.com/cgi/generic/sodbic.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[Na+].OC([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Bicarbonate of soda
Carbonic acid monosodium salt
Sodium acid carbonate
Sodium hydrocarbonate
Sodium hydrogen carbonate
Sodium hydrogencarbonate

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:07 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sodium_bicarbonate

# pKa_Isoelectric_Point:
6.3

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11378618	Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9.
12440699	Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96.
17253467	Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890.
18154426	Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89.
1964114	Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7229

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Hydrogen ions

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB01390
